In the latest trading session, Moderna (MRNA) closed at $42.18, marking a +0.43% move from the previous day. This change lagged the S&P 500's 1.26% gain on the day. Elsewhere, the Dow saw an upswing of 0.8%, while the tech-heavy Nasdaq appreciated by 1.77%.The the stock of biotechnology company has fallen by 2.19% in the past month, leading the Medical sector's loss of 6.56% and the S&P 500's loss of 2.82%.Market participants will be closely following the financial results of Moderna in its upcoming release ...

Originally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising my background in life sciences to assess the potential of novel treatments, including those using CGT, as well as, their capacity to drive shareholders' returns. Thus, as SA analyst, I will be focusing on analysing biotechnology, pharmac ...

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna (MRNA) have been sliding down over the past few years due to waning demand for the vaccine.In the past three months, MRNA stock has lost nearly 40%, significantly underperforming the industry’s 17.1% decline, as seen in the chart below. While the company’s pipeline progress has been encouraging, the update to its business outlook for the next four years and a curtailed R&D budget did not sit well ...

Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "mRNA Vaccines and Therapeutics Market by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-user, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering.The global mRNA vaccines and therapeutics market size reached US$ 57.7 billion in 2023. Looking forward, the market is expected to reach US$ 72.7 billion by 2032, exhibiting a growth rate (CAGR) of 2.6% during 2023-2032. The development and acceptance of mRNA-based ...

Moderna, Inc. (NASDAQ:MRNA) Piper Sandler 36th Annual Healthcare Conference December 5, 2024 10:30 AM ET Company Participants Stephane Bancel - Chief Executive Officer Conference Call Participants Ted Tenthoff - Piper Sandler Ted Tenthoff Good morning, everyone. My name is Ted Tenthoff. I'm the senior private tech analyst at Piper Sandler. And before I begin, I am required to point out certain disclosures regarding the relationship between Piper and our next presenting company, Moderna, which are listed bot ...

Moderna, Inc. (NASDAQ:MRNA) 7th Annual Evercore ISI HealthCONx Conference Call December 4, 2024 1:20 PM ET Company Participants Lavina Talukdar - Senior Vice President and Head of Investor Relations Conference Call Participants Cory Kasimov - Evercore ISI Cory Kasimov Good afternoon, everyone. I'm Cory Kasimov, one of the senior biotech analysts here at Evercore ISI. It's my pleasure to host our next session with Moderna. And as you can see, we have Lavina Talukdar, the Senior Vice President and Head of Inv ...

KEY TAKEAWAYSModerna shares surged further Friday, a day after a senior executive made bullish comments at a healthcare conference about the vaccine maker's pipeline and cash position.Moderna expects to become self-funding by 2028, head of investor relations Lavina Talukdar said at the Jefferies London Healthcare Conference.Moderna stock is down almost 60% this year, however, and—like other vaccine makers—was hit recently by President-elect Donald Trump's nomination of vaccine sceptic Robert F. Kennedy Jr. ...

Moderna, Inc. (NASDAQ:MRNA) Jefferies London Healthcare Conference November 21, 2024 9:00 AM ET Company Participants Lavina Talukdar - IR Conference Call Participants Michael Yee - Jefferies Michael Yee Good afternoon everyone. Thank you for joining us on the next session. This afternoon, we have the pleasure of having Moderna here with us and up on the front is the Head of Investor Relations, who everybody knows, Lavina Talukdar. Thank you for joining us. I would say quite a timely discussion because there ...

Moderna, Inc. (NASDAQ:MRNA) Jefferies London Healthcare Conference November 21, 2024 9:00 AM ET Company Participants Lavina Talukdar - IR Conference Call Participants Michael Yee - Jefferies Michael Yee Good afternoon everyone. Thank you for joining us on the next session. This afternoon, we have the pleasure of having Moderna here with us and up on the front is the Head of Investor Relations, who everybody knows, Lavina Talukdar. Thank you for joining us. I would say quite a timely discussion because there ...

Last week, some large European and U.S. vaccine maker stocks fell in reaction to Robert F. Kennedy Jr.’s nomination to lead the Department of Health and Human Services.Including Moderna Inc MRNA, several stocks witnessed a decline as Kennedy has been known to be against vaccines and has a track record of making false claims about vaccines, including the debunked idea that they cause autism.Goldman Sachs hosted an investor lunch with Moderna CEO Stéphane Bancel, President Stephen Hoge, and Lavina Talukdar, S ...